Search results
Results From The WOW.Com Content Network
The McDonald criteria are diagnostic criteria for multiple sclerosis (MS). These criteria are named after neurologist W. Ian McDonald who directed an international panel in association with the National Multiple Sclerosis Society (NMSS) of America and recommended revised diagnostic criteria for MS in April 2001.
The Poser diagnosis criteria for MS does not allow doctors normally to give an MS diagnosis until a second attack takes place. Therefore, the concept of "clinical MS", for a MS that can be diagnosed is sometimes too strong because until MS diagnosis has been established, nobody can tell whether the disease dealing with is MS. [citation needed]
Multiple sclerosis diagnosis can only be made when there is proof of lesions disseminated in time and in space. Therefore, when damage in the CNS is big enough to be seen. It would be desirable to make it faster. The ideal diagnosis schema would be able to determine for any given subject, if he will develop MS, at any point in his life, and when.
A new study found that in about 10% cases of multiple sclerosis, the body begins producing a distinctive set of antibodies against its own proteins years before symptoms emerge. “Multiple ...
By December 9 – 2025 Sabah state election. [3] [4] The Civil Aviation Authority of Malaysia (CAAM) and the Malaysian Aviation Commission (MAVCOM) will be merged to establish a single national civil aviation body. [5] [6]
February 18. National Drink Wine Day. NBA All-Star Game Day. Pluto Day. World Whale Day. National Battery Day. February 19. Presidents' Day. National Chocolate Mint Day. Tug of War Day. National ...
In March 2017, ocrelizumab was approved in the United States for the treatment of primary progressive multiple sclerosis in adults. [22] [42] It is also used for the treatment of relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. [42]
In fact, it seems that MS patients with anti-MOG positivity could be considered a different disease in the near future. Comparative Effectiveness Research (CER) is an emerging field in Multiple Sclerosis treatment. The response of the disease to the different available medications at this moment cannot be predicted, and would be desirable. [17]